Table 3.
Performance of a single CpG site for detecting early-stage OSCC
| Discrimination statistics |
Cross validation* |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Rank† | CpG site | SPE | SEN | AUC | (95% CI) | AUC | (95% CI) | ||
| 1 | FLT4_E206_F | 1.00 | 0.81 | 0.91 | (0.81, | 1.00) | 0.81 | (0.62, | 1.00) |
| 2.5 | KDR_E79_F | 1.00 | 0.75 | 0.88 | (0.77, | 0.98) | 0.75 | (0.53, | 0.97) |
| 2.5 | TFPI2_P9_F | 1.00 | 0.75 | 0.88 | (0.77, | 0.98) | 0.75 | (0.53, | 0.97) |
| 5 | GSTM2_E153_F | 0.87 | 0.81 | 0.81 | (0.67, | 0.95) | 0.65 | (0.42, | 0.88) |
| 5 | MT1A_P49_R | 0.87 | 0.81 | 0.84 | (0.71, | 0.97) | 0.70 | (0.48, | 0.93) |
| 5 | NPY_E31_R | 0.87 | 0.81 | 0.84 | (0.71, | 0.97) | 0.70 | (0.48, | 0.93) |
| 8.5 | ADCYAP1_P455_R | 0.87 | 0.75 | 0.81 | (0.67, | 0.95) | 0.65 | (0.42, | 0.88) |
| 8.5 | EPHA7_E6_F | 0.87 | 0.75 | 0.81 | (0.67, | 0.95) | 0.65 | (0.42, | 0.88) |
| 8.5 | ESR1_P151_R | 0.80 | 0.88 | 0.84 | (0.70, | 0.97) | 0.70 | (0.47, | 0.93) |
| 8.5 | MYOD1_E156_F | 0.80 | 0.88 | 0.84 | (0.70, | 0.97) | 0.70 | (0.47, | 0.93) |
| 11.5 | HOXB13_P17_R | 0.80 | 0.81 | 0.81 | (0.66, | 0.95) | 0.65 | (0.42, | 0.88) |
| 11.5 | TFPI2_P152_R | 0.80 | 0.81 | 0.81 | (0.66, | 0.95) | 0.65 | (0.42, | 0.88) |
| 13.5 | HS3ST2_P171_F | 0.73 | 0.88 | 0.80 | (0.66, | 0.95) | 0.64 | (0.40, | 0.88) |
| 13.5 | PENK_P447_R | 0.73 | 0.88 | 0.80 | (0.66, | 0.95) | 0.64 | (0.40, | 0.88) |
| 15 | GABRB3_E42_F | 0.80 | 0.75 | 0.78 | (0.62, | 0.93) | 0.60 | (0.36, | 0.84) |
| 16.5 | HS3ST2_P546_F | 0.73 | 0.75 | 0.74 | (0.58, | 0.90) | 0.55 | (0.31, | 0.79) |
| 16.5 | TERT_P360_R | 0.73 | 0.75 | 0.74 | (0.58, | 0.90) | 0.55 | (0.31, | 0.79) |
SPE=specificity ; SEN=sensitivity ; AUC=area under the ROC curve; CI=confidence interval.
†
ranked by AUC (an average rank is assigned for tied AUCs).
*
leave-one-out cross validation.